Bill > HR1796

This bill amends the Public Health Service Act to reauthorize and expand a demonstration program for sickle cell disease prevention and treatment. The bill updates language to focus more specifically on treating sickle cell disease and preventing its complications, broadens the funding mechanisms by allowing grants, contracts, and cooperative agreements, and significantly increases funding from $4,455,000 to $8,205,000 annually through fiscal year 2029. The bill also expresses Congress's sense that further research should be conducted to better understand and potentially find cures for heritable blood disorders, with a particular emphasis on sickle cell disease. Notably, the bill is officially titled the "Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025," reflecting its comprehensive approach to addressing this serious health condition. The changes aim to improve support for research, treatment, and prevention efforts related to sickle cell disease, which is an inherited disorder affecting red blood cells and primarily impacting African Americans.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/1796/all-info